Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neisseria Gonorrhoeae Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Neisseria Gonorrhoeae Infections - Pipeline Review, H1 2015', provides an overview of the Neisseria Gonorrhoeae Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neisseria Gonorrhoeae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neisseria Gonorrhoeae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neisseria Gonorrhoeae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neisseria Gonorrhoeae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neisseria Gonorrhoeae Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neisseria Gonorrhoeae Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neisseria Gonorrhoeae Infections Overview 7 Therapeutics Development 8 Pipeline Products for Neisseria Gonorrhoeae Infections - Overview 8 Pipeline Products for Neisseria Gonorrhoeae Infections - Comparative Analysis 9 Neisseria Gonorrhoeae Infections - Therapeutics under Development by Companies 10 Neisseria Gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 12 Neisseria Gonorrhoeae Infections - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Neisseria Gonorrhoeae Infections - Products under Development by Companies 15 Neisseria Gonorrhoeae Infections - Products under Investigation by Universities/Institutes 16 Neisseria Gonorrhoeae Infections - Companies Involved in Therapeutics Development 17 Actavis plc 17 Adenium Biotech ApS 18 AstraZeneca PLC 19 BioDiem Ltd 20 Biolytics Pharma 21 Debiopharm International S.A. 22 GlaxoSmithKline plc 23 Sarepta Therapeutics, Inc. 24 Sumitomo Dainippon Pharma Co., Ltd. 25 Vertex Pharmaceuticals Incorporated 26 Neisseria Gonorrhoeae Infections - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Arenicin - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 AZD-0914 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BDM-I - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Cribrostatin-6 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 dalbavancin - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Debio-1453 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 gonorrhoeae vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 GSK-2140944 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 SM-295291 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SM-369926 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule to Inhibit Tubulin for Neuroblastoma and Neisseria Gonorrhoeae Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Vaccine for Neisseria Gonorrhoeae Infection - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 VT-12008911 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Neisseria Gonorrhoeae Infections - Recent Pipeline Updates 54 Neisseria Gonorrhoeae Infections - Dormant Projects 64 Neisseria Gonorrhoeae Infections - Product Development Milestones 65 Featured News & Press Releases 65 Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 65 Jun 03, 2014: AstraZeneca's novel antibiotic candidate AZD0914 given Fast Track status by US FDA 67 Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables Number of Products under Development for Neisseria Gonorrhoeae Infections, H1 2015 8 Number of Products under Development for Neisseria Gonorrhoeae Infections - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Neisseria Gonorrhoeae Infections - Pipeline by Actavis plc, H1 2015 17 Neisseria Gonorrhoeae Infections - Pipeline by Adenium Biotech ApS, H1 2015 18 Neisseria Gonorrhoeae Infections - Pipeline by AstraZeneca PLC, H1 2015 19 Neisseria Gonorrhoeae Infections - Pipeline by BioDiem Ltd, H1 2015 20 Neisseria Gonorrhoeae Infections - Pipeline by Biolytics Pharma, H1 2015 21 Neisseria Gonorrhoeae Infections - Pipeline by Debiopharm International S.A., H1 2015 22 Neisseria Gonorrhoeae Infections - Pipeline by GlaxoSmithKline plc, H1 2015 23 Neisseria Gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 24 Neisseria Gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 25 Neisseria Gonorrhoeae Infections - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Neisseria Gonorrhoeae Infections Therapeutics - Recent Pipeline Updates, H1 2015 54 Neisseria Gonorrhoeae Infections - Dormant Projects, H1 2015 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
